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ARTICLE
ABSTRACT
Hypoglycemia, an adverse effect that may develop rapidly and
progress to cause potentially serious consequences over a short
period of time, is difficult to monitor in both outpatients and 
inpatients, and may be associated with serious central nervous
system sequelae. Four recently published cases of severe acute
hypoglycemia with gatifloxacin stimulated a review of the 
published literature and spontaneous adverse drug reaction
reports made in Canada on fluoroquinolone-induced 
hypoglycemia or hyperglycemia. A search of the English literature
for published reports of hypoglycemia associated with
ciprofloxacin, gatifloxacin, levofloxacin, and moxifloxacin
revealed 2 published case reports of hypoglycemia attributed to
the potential drug–drug interaction of an oral hypoglycemic agent
with ciprofloxacin; 4 such reports with gatifloxacin; and no reports
with either levofloxacin or moxifloxacin. All spontaneously
reported adverse drug reactions made to the Canadian Adverse
Drug Reaction Monitoring Program (CADRMP) listed under the
Metabolic and Nutritional Disorders category for the 3 marketed
respiratory fluoroquinolones (gatifloxacin, levofloxacin, and 
moxifloxacin) were then obtained. Altogether, 25 (93%) of 
27 reports in this category were due to either hypoglycemia or
hyperglycemia with gatifloxacin; 4 (11%) of 35 reports, with 
levofloxacin; and 1 (10%) of 10 reports, with moxifloxacin. The
number of case reports for hypoglycemia (x2 = 24; p < 0.001),
hyperglycemia (x2 = 8; p < 0.05), and total (hypoglycemia, 
hyperglycemia, and both hypoglycemia and hyperglycemia) 
(x2 = 46; p < 0.001) was significantly higher for gatifloxacin than
for either levofloxacin or moxifloxacin. The CADRMP reports for
hypoglycemia or hyperglycemia with the respiratory 
fluoroquinolones may have identified a safety signal for 
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RÉSUMÉ
L’hypoglycémie, effet indésirable qui peut survenir rapidement et
dont l’évolution peut entraîner des conséquences graves en 
peu de temps, est difficile à surveiller tant chez les patients 
hospitalisés qu’externes, et peut être associée à de graves
séquelles sur le système nerveux central. Quatre 
cas d’hypoglycémie aiguë grave secondaire à l’administration 
de gatifloxacine publiés récemment ont motivé une revue de 
la littérature et des notifications volontaires des effets indésirables
des médicaments au Canada relatives à l’hypoglycémie et à 
l’hyperglycémie attribuables aux fluoroquinolones. Une recherche
bibliographique de rapports publiés en anglais sur l’hypoglycémie
associée à l’administration de ciprofloxacine, de gatifloxacine, de
lévofloxacine et de moxifloxacine ont mis au jour deux rapports
de cas d’hypoglycémie attribuable à l’interaction médicamenteuse 
potentielle entre un hypoglycémiant oral et la ciprofloxacine, 
quatre en relation avec la gatifloxacine et aucun en relation avec
la lévofloxacine ou la moxifloxacine. Toutes les notifications
volontaires d’effets indésirables des médicaments effectuées dans
le cadre du Programme canadien de surveillance des effets
indésirables des médicaments (PCSEIM), dans la catégorie 
troubles du métabolisme et de la nutrition, relativement aux trois
fluoroquinolones respiratoires commercialisées (gatifloxacine,
lévofloxacine et moxifloxacine) ont par la suite été obtenues.
Dans l’ensemble, 25 rapports sur 27 (93 %) dans cette catégorie
étaient attribuables à des cas d’hypoglycémie ou d’hyperglycémie
causées par la gatifloxacine; 4 sur 35 (11 %) à des cas causés par
la lévofloxacine, et 1 sur 10 (10 %) à un cas causé par la 
moxifloxacine. Le nombre de rapports de cas d’hypoglycémie 
(x2 = 24; p < 0,001), d’hyperglycémie (x2 = 8; p < 0,05), et de cas
totaux (hypoglycémie, hyperglycémie et les deux à la fois) 
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INTRODUCTION
Currently, 6 known class-related adverse reactionsare associated with fluoroquinolones: phototoxicity,
QTc prolongation, central nervous system toxicity, 
tendonitis or tendon rupture, hepatotoxicity, and 
alterations in blood glucose (either hypoglycemia or
hyperglycemia). Postmarketing experience has indicated
that the propensity for causing class-related adverse
reactions is not uniform amongst the fluoroquinolones.1
For example, temafloxacin was withdrawn from the
market as a result of reports of patients having severe
hypoglycemia, hepatic and renal dysfunction, hemolytic
anemia, and anaphylaxis after taking the drug2; similarly,
grepafloxacin was withdrawn by the manufacturer
because of reports of cardiovascular death and QTc 
prolongation3; and trovafloxacin became a limited-use
drug as a result of reports of serious liver toxicity,
including death.1 The systemically active fluoroquinolones
that are currently available in Canada are ciprofloxacin
(IV or PO), gatifloxacin (IV or PO), levofloxacin (IV or
PO), moxifloxacin (IV or PO), and ofloxacin (PO).
Hypoglycemia is an adverse effect that may develop
rapidly and progress to cause potentially serious 
consequences over a short period of time. Patients with
type 2 diabetes taking oral hypoglycemic agents have a
relatively low incidence of hypoglycemic episodes, and
those that do occur tend not to be severe enough to
result in reduced consciousness, causing the patient to
require assistance (e.g., an injection of glucagon).
Unlike patients with type 1 diabetes who take insulin
injections and frequently monitor their own blood 
glucose levels, those with type 2 diabetes are less likely
to be aware that they are developing hypoglycemia and
are less prepared to take appropriate action to prevent
its progression to severe hypoglycemia. Although 
serious hypoglycemia during fluoroquinolone therapy
seems to be rare, the potential for serious central 
nervous system sequelae, including convulsions and
coma, with possible permanent neurological deficit, is
of concern.
Menzies and others4 reported 3 cases of severe, 
persistent hypoglycemia attributed to gatifloxacin in
hospitalized older adults (> 70 years old) with diabetes
mellitus who were taking oral hypoglycemic agents.
Each of the 3 patients experienced a rapid decline in
blood glucose to very low levels (< 2 mmol/L) at 1 to
15 h after the first dose of gatifloxacin. Administration of
oral hypoglycemic agents was temporarily interrupted,
and administration of multiple bolus doses of IV 
dextrose 50% or an IV infusion of hypertonic dextrose,
or both, were required to restore and maintain 
normoglycemia. Hypoglycemia seemed to resolve upon
discontinuation of gatifloxacin and did not recur, despite
resumption of oral hypoglycemic drug administration.
Baker and Hangii5 published a fourth case report of
hypoglycemia caused by gatifloxacin. A 73-year-old man
with type 2 diabetes mellitus came to the emergency
department with a blood glucose value of 1.2 mmol/L
on the fourth day of gatifloxacin treatment. He had
never before experienced symptomatic hypoglycemia
while taking his antidiabetic medications. Despite 
discontinuation of glyburide and metformin, and 
IV administration of 3 doses of 50% dextrose, he
required a continuous infusion of hypertonic dextrose
and 3 further bolus doses of 50% dextrose over a 
24-h period to maintain normoglycemia. Assessing the
reaction for causality using the Naranjo probability scale6
for adverse drug reactions, Baker and Hangii5
categorized the reaction as possibly caused by 
gatifloxacin.
These recently published case reports4,5 of severe
acute hypoglycemia with gatifloxacin stimulated this
group from Sunnybrook and Women’s College Health
gatifloxacin. A systematic analysis to determine causality, risk 
factors, and incidence of hypoglycemia or hyperglycemia may 
be warranted.
Key words: fluoroquinolones, gatifloxacin, hypoglycemia, 
hyperglycemia
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(x2 = 46; p < 0,001) était considérablement plus élevé pour la 
gatifloxacine que pour la lévofloxacine ou la moxifloxacine. Les 
rapports de cas d’hypoglycémie ou d’hyperglycémie aux 
fluoroquinolones respiratoires déclarés au PCSEIM pourraient
bien avoir dégagé un signal d’alerte quant à l’utilisation de la 
gatifloxacine. Une analyse systématique permettant de déterminer
la cause, les facteurs de risque et l’incidence des cas 
d’hypoglycémie ou d’hyperglycémie semble justifiée.
Mots clés : fluoroquinolones, gatifloxacine, hypoglycémie, 
hyperglycémie
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Sciences Centre, Toronto, Ontario, to review the 
published literature and the spontaneous adverse 
drug reaction (ADR) reports completed in Canada 
on fluoroquinolone-induced hypoglycemia or 
hyperglycemia as part of our institutional formulary
review of available respiratory fluoroquinolones. The
results of this review are presented here.
REVIEW OF THE EVIDENCE
Review of the Literature
A literature search for published reports of 
hypoglycemia associated with ciprofloxacin, 
gatifloxacin, levofloxacin, and moxifloxacin was 
completed with SUMSearch (http://sumsearch.uthscsa.edu)
to retrieve English medical evidence up to June 10,
2003. SUMSearch is a tool that combines searches of
textbooks (emedicine, PubMed), practice guidelines
(National Guideline Clearinghouse, PubMed), systematic
reviews (DARE, which includes Cochrane abstracts;
PubMed), and original research (PubMed). In addition,
reference lists of relevant publications on fluoro-
quinolones were reviewed to identify publications that
might not have been retrieved with the search tool.
The literature search revealed 2 published reports7,8
of hypoglycemia attributed to a potential drug–drug 
interaction of an oral hypoglycemic agent with ciprofloxacin,
and no reports with either levofloxacin or moxifloxacin.
The observed drug interaction with glyburide 
and ciprofloxacin observed in the 2 case reports7,8 is 
postulated to be the result of the inhibition of the 
component of the metabolism of glyburide involving the
P-450 CYP3A4 enzyme.7 Ciprofloxacin is known to 
competitively inhibit the CYP3A4 isoform, although the
clinical relevance of this has not been established.9 The
widespread postmarketing use of both ciprofloxacin
and levofloxacin and the scarcity of published reports 
of drug-induced hypoglycemia by either a drug–drug 
interaction or a direct effect suggests that symptomatic
hypoglycemia would be an extremely rare risk with
these agents.
In addition to the 4 published case reports of 
hypoglycemia with gatifloxacin,4,5 3 studies10-12 evaluating
the effect of gatifloxacin on glucose homeostasis have
been published. Each of these published papers was
completed by investigators employed by Bristol-Myers
Squibb. The first study,10 published only as an abstract,
evaluated the effect of multiple-dose gatifloxacin on 
glucose tolerance, glucose and insulin homeostasis, and
glyburide pharmacokinetics in patients with type 2 
diabetes mellitus. This study concluded that gatifloxacin
was well tolerated in the 34 study patients on oral 
glyburide; had no effect on the oral glucose tolerance
test, or on glucose or insulin homeostasis; and had no
pharmacokinetic or pharmacodynamic interaction with
glyburide. However, neither the parameters used to
define significant changes in the oral glucose tolerance
test or in glucose and insulin homeostasis, nor the 
values observed for these parameters were presented 
in the abstract, making interpretation of the findings 
difficult.
The second study11 was a dose-escalation study of
the safety, tolerability, and pharmacokinetics of 
IV gatifloxacin in healthy adult men. This study 
concluded that there were no significant differences 
in fasting blood glucose, insulin, or C-peptide 
concentrations between those given a placebo and
those given gatifloxacin in doses from 200 to 800 mg 
IV as a 1-h infusion for 14 days. The investigators
described mild-to-moderate transient decreases in 
fasting blood glucose in healthy adult men at the end 
of the infusions, but did not provide any specific 
quantification.
The final published study12 evaluated the effect of
multiple-dose gatifloxacin or ciprofloxacin on glucose
homeostasis and insulin production in patients with type
2 diabetes mellitus whose condition was controlled with
diet and exercise. This randomized, double-blind, 
placebo-controlled, multiple-dose study concluded that 
gatifloxacin was well tolerated and had no significant
effect on glucose homeostasis, ß-cell function, or long-
term fasting blood-glucose levels.
Lack of effect in this study12 was defined as 90% 
confidence intervals of 0.67 to 1.5 for the ratio of the
means of treatment (either gatifloxacin or ciprofloxacin)
to those of the placebo. Therefore, a statistically 
significant event would require a reduction in the area
under the curve for either glucose or insulin of at least
43%, or an increase of at least 50%. The assignment of
this ratio for significance was not explained or 
referenced. The investigators observed mean values for
the area under the curve for fasting glucose levels that
were 27% and 15% lower for gatifloxacin than for the
placebo on days 1 and 10, respectively. Based on their
definition of statistical significance, these results were
not considered significant.
However, these drops may be clinically important.
For example, a patient with a fasting glucose level of 
4 mmol/L who experiences a 25% reduction in fasting
glucose level with gatifloxacin, resulting in a low fasting
glucose level of 3 mmol/L, may experience symptomatic
hypoglycemia. In addition, the investigators12 observed a
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mean area under the curve for fasting insulin levels that
was significantly higher (43%) for gatifloxacin than for
the placebo on day 1 (p < 0.05).
The respiratory fluoroquinolones (levofloxacin, 
gatifloxacin, and moxifloxacin) do not affect the P-450
isoenzyme system.13 The mechanism by which these 
fluoroquinolones may affect blood glucose levels is 
not clear. However, it has been hypothesized that 
fluoroquinolones may directly stimulate pancreatic ß-cell
function to cause an increased release of insulin, resulting
in a decrease in blood glucose concentrations.12
Review of Spontaneously Reported Adverse
Drug Reactions Made to the Canadian
Adverse Drug Reaction Monitoring Program
After a review of the published literature, all 
spontaneously reported ADRs of either hypoglycemia or
hyperglycemia submitted to Health Canada’s Adverse
Drug Reaction Monitoring Program (CADRMP) were
obtained. The CADRMP coordinates national spontaneous
ADR reporting in Canada. Spontaneous or voluntary ADR
reporting in Canada may be done by patients, health care
professionals, or manufacturers. However, manufacturers
and market authorization holders in Canada are 
mandated to report adverse reactions to Health Canada,
according to section C.01.016 of the Food and Drug 
Regulations.14 The CADRMP tracks reports of 
hypoglycemia or hyperglycemia in a category called
Metabolic and Nutritional Disorders. All the Metabolic and
Nutritional Disorder case reports for each respiratory 
fluoroquinolone from the CADRMP that were entered into
the CADRMP database were obtained from the date that
each respiratory fluoroquinolone was marketed to
December 31, 2002, inclusive. Based on the date of 
marketing, the reporting periods were 2 years for 
gatifloxacin, 5 years for levofloxacin, and 2 years 
for moxifloxacin.
Of a total of 27 different reports made in the
Metabolic and Nutritional Disorders category for 
gatifloxacin, 25 (93%) were due to either hypoglycemia
or hyperglycemia (Figure 1), whereas 11% (4/35) of
reports for levofloxacin and 10% (1/10) of reports for
moxifloxacin were due to either hypoglycemia 
or hyperglycemia. The number of case reports in 
the Metabolic and Nutritional Disorders category 
for hypoglycemia (x2 = 24; p < 0.001), hyperglycemia 
(x2 = 8; p < 0.05), and total (i.e., hypoglycemia, 
hyperglycemia, and both hypoglycemia and 
hyperglycemia) (x2 = 46; p < 0.001) were significantly
higher for gatifloxacin than either levofloxacin or 
moxifloxacin (Figure 1).
Since the application of the x2 statistic may be 
inaccurate for small sample sizes or when a given cell
value is less than 5, the analysis was confirmed by
means of the Fisher’s exact test with Bonferroni’s 
correction of the p value to ensure that the risk of a 
type I error did not exceed 5%, even with multiple 
comparisons (i.e., gatifloxacin versus levofloxacin, 
gatifloxacin versus moxifloxacin, and levofloxacin 
versus moxifloxacin) per analysis (i.e., hypoglycemia,
hyperglycemia, and total). From the Bonferroni’s error
rate correction, it was determined that a statistically 
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Figure 1. Metabolic and nutritional spontaneous adverse
drug reports to the Canadian Adverse Drug Reaction
Monitoring Program from the date the antibiotic was first
marketed to December 31, 2002: gatifloxacin, 2 years
(January 1, 2001, to December 31, 2002); levofloxacin, 
5 years (January 1, 1998, to December 31, 2002); 
moxifloxacin, 2 years (January 1, 2001, to January 17,
2003). *The number of total case reports for 
hypoglycemia, hyperglycemia, and both hypoglycemia and
hyperglycemia with gatifloxacin is significantly higher than
the number for either levofloxacin or moxifloxacin (x2 for
equality of proportions = 46, p < 0.001, Fisher’s exact 
test, p < 0.0001). †The number of case reports for 
hypoglycemia with gatifloxacin is significantly higher than
the number for either levofloxacin or moxifloxacin (x2 for
equality of proportions = 24, p < 0.001, Fisher’s exact 
test, p < 0.008). ‡The number of case reports for 
hyperglycemia with gatifloxacin is significantly higher 
than the number for either levofloxacin or moxifloxacin
with x2 for equality of proportions (x2 = 8, p < 0.05), 
but not with Fisher’s exact test (p > 0.0169).
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significant two-tailed p value of < 0.0169 was needed for
the Fisher’s exact test to maintain a type I error rate of
< 5%. With the Fisher’s exact test, the number of 
case reports in the Metabolic and Nutritional Disorders 
category for hypoglycemia (p <0.008) and total 
(hypoglycemia, hyperglycemia, and both hypoglycemia
and hyperglycemia) (p < 0.0001) remained statistically
higher with gatifloxacin than with levofloxacin and
moxifloxacin. However, the Fisher’s exact test 
comparing respiratory fluoroquinolones for the number
of cases of hyperglycemia did not reach statistical 
significance (gatifloxacin versus levofloxacin, p = 0.04,
and gatifloxacin versus moxifloxacin, p = 0.16).
DISCUSSION
The Canadian Adverse Reaction Newsletter
published a review15 of the CADRMP reports for 
hypoglycemia and hyperglycemia with gatifloxacin in
July 2003. The mandate of the CADRMP newsletter is to
alert health care professionals to potential signals 
detected from a review of case reports submitted to
Health Canada. This report indicated that 44% of all
ADR reports made for gatifloxacin from February 21,
2001, to February 28, 2003, were due to abnormal 
glucose metabolism and that a total of 28 reports of
abnormal glucose metabolism were made during this
period.15
Analysis of abnormal glucose metabolism with 
gatifloxacin in the current review included only those
reports provided by CADRMP from January 1, 2001, to
December 31, 2002, and consisted of 25 different
reports. Letourneau and others15 indicated that 
hypoglycemia and hyperglycemia were reported more
frequently with gatifloxacin than with other 
fluoroquinolones; however, they did not conduct a 
statistical analysis to demonstrate this. The current review’s
analysis of reports made with each of the respiratory 
fluoroquinolones approved for use in Canada provides
the statistical analysis that supports the conclusion of
Letourneau and others15. Since the number of cases of 
hyperglycemia with gatifloxacin in the current analysis
was significantly higher with x2 analysis (x2 = 8; p < 0.05),
but not with the Fisher’s exact test, a type II error 
resulting from an insufficient sample size cannot be
ruled out in the statistical comparisons for hyperglycemia.
The gatifloxacin (Tequin) product monograph16 was
recently revised (December 2002) by the manufacturer
to provide more information about the glucose 
dysregulation reported during the postmarketing 
experience. The monograph recommends careful 
monitoring of blood glucose when gatifloxacin is
administered to patients with diabetes. The prescribing
information warns that hypoglycemic episodes may be
severe and potentially life-threatening, and tend to
occur early in the therapy (in the initial 1 to 3 days). In
addition, the monograph states that hyperglycemia
tends to occur later in the course of treatment (from 
4 to 10 days after initiation of therapy) and may be
severe, manifesting as hyperglycemic hyperosmolar 
syndrome (or coma). Based on the postmarketing
surveillance of 15 000 patients, the manufacturer 
estimates that the incidence of hypoglycemia and 
hyperglycemia for patients with diabetes is 0.64% and
1.30%, respectively. In nondiabetic patients, the 
corresponding incidence values quoted by the 
manufacturer are 0.030% and 0.007%, respectively.16
The limitations of reviewing spontaneous ADR
reports include an inability to determine the incidence
or causality of an ADR, since ADRs are underreported
and the actual population exposure is unknown.17-19
Many factors may influence the reporting of ADRs,
including the length of time that a product has been on
the market, approved indications, prescription and
drug-use practices, geographic location, publication in
scientific journals, and issuance of risk advisories. 
However, the CADRMP reports may identify potential
safety signals associated with a marketed drug. Although
identification of a signal with a given drug does not
imply causation to the adverse reaction, it should
prompt investigation of a potential association between
the drug and the occurrence of a given toxicity.
The results of this review indicate that the CADRMP
reports for hypoglycemia or hyperglycemia with 
gatifloxacin compared with either levofloxacin or 
moxifloxacin may have identified a safety signal for 
gatifloxacin. A systematic analysis to determine 
causality, risk factors, and incidence of hypoglycemia or
hyperglycemia may be warranted.
References
1. Leone R, Venegoni M, Motola D, Moretti U, Piazzetta V, Cocci
A, et al. Adverse drug reactions related to the use of 
fluoroquinolone antimicrobials: an analysis of spontaneous
reports and fluoroquinolone consumption data from three 
Italian regions. Drug Saf 2003;26:109-20.
2. Blum MD, Graham DJ, McCloskey CA. Temafloxacin syndrome:
review of 95 cases. Clin Infect Dis 1994;18:946-50.
3. Ball P, Mandell L, Niki Y, Tillotson G. Comparative tolerability
of the newer fluoroquinolone antibacterials. Drug Saf
1999;21:407-21.
4. Menzies DJ, Dorsainvil PA, Cunha BA, Johnson DH. Severe and
persistent hypoglycemia due to gatifloxacin interaction with
oral hypoglycemic agents. Am J Med 2002;113:232-4.
5. Baker SE, Hangii MC. Possible gatifloxacin-induced hypo-
glycemia. Ann Pharmacother 2002;36:1722-6.
17C J H P – Vol. 57, No. 1 – February 2004 J C P H – Vol. 57, no 1 – février 2004
6. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA,
et al. A method for estimating the probability of adverse drug
reactions. Clin Pharmacol Ther 1981;30:239-45.
7. Roberge RJ, Kaplan R, Frank R, Fore C. Glyburide–ciprofloxacin
interaction with resistant hypoglycemia. Ann Emerg Med
2000;36:160-3.
8. Whiteley M, Worlding J, Patel S, Gibbs KB. Hyopglycaemia in a
diabetic patient, associated with ciprofloxacin therapy [case
report]. Pract Diabetes 1993;10:35.
9. McLellan RA, Drobitch RK, Monshouwer M, Renton KW. 
Fluoroquinolone antibiotics inhibit cytochrome P450-mediated
microsomal drug metabolism in rat and human. Drug Metab
Dispos 1996;24:1134-8.
10. Grasela D, LaCreta F, Kollia GD, Randall D, Stoltz R, Berger S.
Lack of effect of multiple dose gatifloxacin (GAT) on oral 
glucose tolerance (OGTT), glucose and insulin homeostasis,
and glyburide pharmacokinetics (PK) in patients with type II
non-insulin dependent diabetes mellitus (NIDDM) [abstract
196]. In: Proceedings and Abstracts of the 39th Interscience
Conference on Antimicrobial Agents and Chemotherapy; 1999
Sep 26-29; San Francisco, CA.
11. Gajjar DA, LaCreta FP, Uderman HD, Kollia GD, Duncan G,
Birkhofer MJ, et al. A dose-escalation study of the safety, 
tolerability, and pharmacokinetics of intravenous gatifloxacin in
healthy adult men. Pharmacotherapy 2000;20(6 Pt 2):49S-58S.
12. Gajjar DA, LaCreta FP, Kollia GD, Stolz RR, Berger S, Smith WB,
et al. Effect of multiple-dose gatifloxacin or ciprofloxacin on
glucose homeostasis and insulin production in patients with
noninsulin-dependent diabetes mellitus maintained with diet
and exercise. Pharmacotherapy 2000;20(6 Pt 2):76S-86S.
13. Cozza KL, Armstrong SC. Infectious diseases. In: Hales RE, 
editor. The cytochrome P450 system, drug interaction principles 
for medical practice. 1st ed. Washington (DC): American 
Psychiatric Publishing Inc.; 2001. p. 139-62.
14. Health Canada. Consolidation of Food and Drugs Act and Food
and Drugs Regulations. Adverse Drug Reaction Reporting,
Drugs Division, Part C, C.01.016. August 26th 1998. Ottawa
(ON): Health Canada; 2003. p. 401. Available at: http://www.hc-
sc.gc.ca/food-aliment/friia-raaii/food_drugs-aliments_drogues/act-
loi/pdf/e_e-drugs.pdf. Accessed 2003 Oct 14.
15. Letourneau G, Morrison H, McMorran M. Gatifloxacin
(Tequin™): hypoglycemia and hyperglycemia. Can Adverse
React Newsl 2003;13:1-2.
16. Bristol-Myers Squibb Canada Inc. Tequin product monograph.
Montreal (QC); revised 2002 Dec 24.
17. Brewer T, Colditz GA. Postmarketing surveillance and adverse
drug reactions: current perspectives and future needs. JAMA
1999;281:824-9.
18. Miremont G, Haramburu F, Begaud B, Pere JC, Dangoumau J.
Adverse drug reactions: physicians’ opinions versus a causality
assessment method. Eur J Clin Pharmacol 1994;46:285-9.
19. Wallenstein EJ, Fife D. Temporal patterns of NSAID 
spontaneous adverse event reports: the Weber effect revisited.
Drug Saf 2001;24:233-7.
Sandra A.N. Tailor, PharmD, FCSHP, is Coordinator, Infectious 
Diseases, Pharmacy Department, Sunnybrook and Women’s College
Health Sciences Centre, Toronto, Ontario, and Assistant Professor,
Faculty of Pharmacy, University of Toronto, Toronto, Ontario.
Andrew E. Simor, MD, is Head, Department of Microbiology, and
Infectious Diseases Consultant, Division of Infectious Diseases, 
Sunnybrook and Women’s College Health Sciences Centre, Toronto,
Ontario.
William Cornish, BScPhm, is Supervisor, Drug Information, 
Sunnybrook and Women’s College Health Sciences Centre, Toronto,
Ontario.
Elizabeth Phillips, MD, is Head (Acting), Division of Clinical 
Pharmacology, and Staff, Division of Infectious Diseases, Sunnybrook
and Women’s College Health Sciences Centre, and Program Director
Clinical Pharmacology, University of Toronto, Toronto, Ontario.
Sandra Knowles, BScPhm, is Drug Safety Pharmacist, Sunnybrook
and Women’s College Health Sciences Centre, Toronto, Ontario.
Anita Rachlis, MD, is Head, Division of Infectious Diseases, 
Sunnybrook and Women’s College Health Sciences Centre, and 
Professor, Division of Infectious Diseases, Department of Medicine,
University of Toronto, Toronto, Ontario.
Address correspondence to:
Dr Sandra A.N. Tailor
Coordinator—Infectious Diseases
Pharmacy Department
Sunnybrook and Women's College Health Sciences Centre
2075 Bayview Avenue
E-302
Toronto ON
M4N 3M5
e-mail: sandra.tailor@sw.ca
Acknowledgements
The authors have received funding, research sponsorship, and 
contract work from Bayer Inc., Bristol-Myers Squibb Canada Inc., and
Janssen-Ortho Inc. However, this paper has not been sponsored,
endorsed, reviewed, or made available in advance of publication to
any of these companies.
